- Home
- ATRA vs VYNE Comparison
ATRA vs VYNE Comparison
Compare ATRA & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRA
- VYNE
- Stock Information
- Founded
- ATRA 2012
- VYNE 2003
- Country
- ATRA United States
- VYNE United States
- Employees
- ATRA N/A
- VYNE N/A
- Industry
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- ATRA Health Care
- VYNE Health Care
- Exchange
- ATRA Nasdaq
- VYNE Nasdaq
- Market Cap
- ATRA 40.1M
- VYNE 35.7M
- IPO Year
- ATRA 2014
- VYNE 2018
- Fundamental
- Price
- ATRA $8.00
- VYNE $0.93
- Analyst Decision
- ATRA Buy
- VYNE Strong Buy
- Analyst Count
- ATRA 5
- VYNE 2
- Target Price
- ATRA $17.75
- VYNE $6.25
- AVG Volume (30 Days)
- ATRA 78.7K
- VYNE 261.2K
- Earning Date
- ATRA 05-15-2025
- VYNE 05-08-2025
- Dividend Yield
- ATRA N/A
- VYNE N/A
- EPS Growth
- ATRA N/A
- VYNE N/A
- EPS
- ATRA N/A
- VYNE N/A
- Revenue
- ATRA $199,732,000.00
- VYNE $605,000.00
- Revenue This Year
- ATRA N/A
- VYNE N/A
- Revenue Next Year
- ATRA N/A
- VYNE N/A
- P/E Ratio
- ATRA N/A
- VYNE N/A
- Revenue Growth
- ATRA 475.53
- VYNE 43.03
- 52 Week Low
- ATRA $5.01
- VYNE $0.92
- 52 Week High
- ATRA $18.71
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- ATRA 61.05
- VYNE 24.67
- Support Level
- ATRA $7.44
- VYNE $0.96
- Resistance Level
- ATRA $8.10
- VYNE $1.09
- Average True Range (ATR)
- ATRA 0.53
- VYNE 0.08
- MACD
- ATRA 0.09
- VYNE -0.01
- Stochastic Oscillator
- ATRA 92.28
- VYNE 1.95
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.